Trial · NCT02351934
Early Diuresis Following Colorectal Surgery
NCT02351934, Phase 4, Completed, Mayo Clinic; results first posted 2017-06-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Early Diuresis Following Colorectal Surgery. Trials, record NCT02351934. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02351934
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Early Diuresis Following Colorectal Surgery
- NCT number
- NCT02351934
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 123 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Colorectal Disorders
- Interventions
- Furosemide, Celecoxib, Gabapentin
- First posted
- 2015-01-30
- Last updated
- 2018-05-07
- Results first posted
- 2017-06-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Length of Hospital Stay | Up to 7 days | Participants will be followed for the duration of hospital stay, an expected average of 2-7 days. |
| Secondary | Number of Participants Readmitted to Mayo Clinic Within 30-days | Within 30 days of release from hospital | |
| Secondary | Number of Participants Requiring Nasogastric Tube Placement | Up to 7 days | |
| Secondary | Time to Stool Output | Up to 4 days | |
| Secondary | Number of Participants With Acute Kidney Injury | Up to 7 days | Acute kidney injury (AKI) refers to an abrupt decrease in kidney function, resulting in the retention of urea and other nitrogenous waste products and in the dysregulation of extracellular volume and electrolytes. The term AKI has largely replaced acute renal failure (ARF), reflecting the recognition that smaller decrements in kidney function that do not result in overt organ failure are of substantial clinical relevance and are associated with increased morbidity and mortality. The AKI experienced by these patients was not considered an adverse event. |
| Secondary | Number of Participants With Hypokalemia | Up to 7 days | Hypokalemia is generally defined as a serum potassium level of less than 3.5 mmol/L. |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Length of Hospital Stay | Up to 7 days | Intent to treat analysis | hours | MEDIAN |
| SECONDARY | Number of Participants Readmitted to Mayo Clinic Within 30-days | Within 30 days of release from hospital | Intention to treat analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Requiring Nasogastric Tube Placement | Up to 7 days | Intention to Treat Analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to Stool Output | Up to 4 days | Intention to treat analysis | hours | MEDIAN |
| SECONDARY | Number of Participants With Acute Kidney Injury | Up to 7 days | Intention to treat analysis | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Hypokalemia | Up to 7 days | Intention to treat analysis | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Length of Hospital Stay | Furosemide + Enhanced Recovery After Surgery (ERAS) | 99.6 | Inter-Quartile Range 73.1 to 150.6 | hours | |
| Length of Hospital Stay | Enhanced Recovery After Surgery (ERAS) | 80.6 | Inter-Quartile Range 73.6 to 124.0 | hours | |
| Number of Participants Readmitted to Mayo Clinic Within 30-days | Furosemide + Enhanced Recovery After Surgery (ERAS) | 13 | Participants | ||
| Number of Participants Readmitted to Mayo Clinic Within 30-days | Enhanced Recovery After Surgery (ERAS) | 10 | Participants | ||
| Number of Participants Requiring Nasogastric Tube Placement | Furosemide + Enhanced Recovery After Surgery (ERAS) | 6 | Participants | ||
| Number of Participants Requiring Nasogastric Tube Placement | Enhanced Recovery After Surgery (ERAS) | 1 | Participants | ||
| Time to Stool Output | Furosemide + Enhanced Recovery After Surgery (ERAS) | 48.8 | Inter-Quartile Range 27.8 to 82.2 | hours | |
| Time to Stool Output | Enhanced Recovery After Surgery (ERAS) | 45.4 | Inter-Quartile Range 22.7 to 68.8 | hours | |
| Number of Participants With Acute Kidney Injury | Furosemide + Enhanced Recovery After Surgery (ERAS) | 2 | Participants | ||
| Number of Participants With Acute Kidney Injury | Enhanced Recovery After Surgery (ERAS) | 2 | Participants |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow14
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Allocation | STARTED | Furosemide + Enhanced Recovery After Surgery (ERAS) | 62 | |
| Allocation | STARTED | Enhanced Recovery After Surgery (ERAS) | 61 | |
| Allocation | Received Allocation | Furosemide + Enhanced Recovery After Surgery (ERAS) | 56 | |
| Allocation | Received Allocation | Enhanced Recovery After Surgery (ERAS) | 61 | |
| Allocation | COMPLETED | Furosemide + Enhanced Recovery After Surgery (ERAS) | 56 | |
| Allocation | COMPLETED | Enhanced Recovery After Surgery (ERAS) | 61 | |
| Allocation | NOT COMPLETED | Furosemide + Enhanced Recovery After Surgery (ERAS) | 6 | |
| Allocation | NOT COMPLETED | Enhanced Recovery After Surgery (ERAS) | 0 | |
| Follow-Up | STARTED | Furosemide + Enhanced Recovery After Surgery (ERAS) | 56 | |
| Follow-Up | STARTED | Enhanced Recovery After Surgery (ERAS) | 61 |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 participant flowAdverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Decreased Potassium | Blood and lymphatic system disorders | Furosemide + Enhanced Recovery After Surgery (ERAS) | 2 | 62 | 2 |
| other | Decreased Potassium | Blood and lymphatic system disorders | Enhanced Recovery After Surgery (ERAS) | 3 | 61 | 3 |
| other | Increased Serum Creatinine | Renal and urinary disorders | Furosemide + Enhanced Recovery After Surgery (ERAS) | 2 | 62 | 2 |
| other | Increased Serum Creatinine | Renal and urinary disorders | Enhanced Recovery After Surgery (ERAS) | 0 | 61 | 0 |
| other | Decreased blood pressure | Cardiac disorders | Furosemide + Enhanced Recovery After Surgery (ERAS) | 3 | 62 | 3 |
| other | Decreased blood pressure | Cardiac disorders | Enhanced Recovery After Surgery (ERAS) | 0 | 61 | 0 |
| other | Atrial Fibrillation | Cardiac disorders | Furosemide + Enhanced Recovery After Surgery (ERAS) | 1 | 62 | 1 |
| other | Atrial Fibrillation | Cardiac disorders | Enhanced Recovery After Surgery (ERAS) | 0 | 61 | 0 |
| other | Urine leak | Renal and urinary disorders | Furosemide + Enhanced Recovery After Surgery (ERAS) | 0 | 62 | 0 |
| other | Urine leak | Renal and urinary disorders | Enhanced Recovery After Surgery (ERAS) | 1 | 61 | 1 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Furosemide + Enhanced Recovery After Surgery (ERAS) | 0 | 62 |
| Total, all-cause mortality | Enhanced Recovery After Surgery (ERAS) | 0 | 61 |
| Total, other adverse events | Furosemide + Enhanced Recovery After Surgery (ERAS) | 8 | 62 |
| Total, other adverse events | Enhanced Recovery After Surgery (ERAS) | 3 | 61 |
| Total, serious adverse events | Furosemide + Enhanced Recovery After Surgery (ERAS) | 0 | 62 |
| Total, serious adverse events | Enhanced Recovery After Surgery (ERAS) | 0 | 61 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR000135 | Mayo Clinic Center for Clinical and Translational Science (CCaTS) | KHOSLA, SUNDEEP | MAYO CLINIC ROCHESTER | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2012 to 2015 |
Source NIH RePORTER
Trial comparisons6
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Furosemide + Enhanced Recovery After Surgery (ERAS) vs Enhanced Recovery After Surgery (ERAS): Number of Participants With Hypokalemia | Trial comparisons |
| Furosemide + Enhanced Recovery After Surgery (ERAS) vs Enhanced Recovery After Surgery (ERAS): Number of Participants Readmitted to Mayo Clinic Within 30-days | Trial comparisons |
| Furosemide + Enhanced Recovery After Surgery (ERAS) vs Enhanced Recovery After Surgery (ERAS): Number of Participants With Acute Kidney Injury | Trial comparisons |
| Furosemide + Enhanced Recovery After Surgery (ERAS) vs Enhanced Recovery After Surgery (ERAS): deaths from any cause | Trial comparisons |
| Furosemide + Enhanced Recovery After Surgery (ERAS) vs Enhanced Recovery After Surgery (ERAS): Number of Participants Requiring Nasogastric Tube Placement | Trial comparisons |
| Furosemide + Enhanced Recovery After Surgery (ERAS) vs Enhanced Recovery After Surgery (ERAS): serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02351934
GET https://conductscience.org/api/trials/v1/NCT02351934/registered